# Nuclide record nct05142696 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct05142696/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct05142696", "NCT05142696" ;
  schema:name "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab"@en ;
  schema:description "A phase 1/2 trial of Lutetium-177 dotatate, FAP-2286, Atezolizumab in small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct05142696/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05142696> ;
  nuclide:status "active" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/sclc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/fap-2286/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> .